Biotech | March 20, 2024
Lonza to buy US biologics site from Roche for US$ 1.2 billion
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Lonza plans to invest approximately CHF 500 million to upgrade the facility
To accelerate the development of next-generation radioconjugates to treat cancer
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
A five-day inspection was concluded successfully with no critical and no major observations raised
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
More than 10,000 scientific publications containing EUDRAGIT
Subscribe To Our Newsletter & Stay Updated
